Stellar Cyber Honored With 2025 MSP Today Product of the Year Award
Open Security Operations Platform Honored for Exceptional Innovation and Successful Deployment Through the Channel
SAN JOSE, Calif., June 16, 2025--(BUSINESS WIRE)--Stellar Cyber, the cybersecurity illumination company, today announced that its solution, the Stellar Cyber Open Security Operations Platform, has been named a 2025 MSP Today Product of the Year Award winner by TMC, a leading global media company recognized for building communities in technology and business through live events and digital marketing platforms.
The MSP Today Product of the Year Award honors standout products and services that are reshaping the managed services landscape, delivered through the Channel and purpose-built to meet the evolving needs of end users. The Stellar Cyber Open Security Operations Platform was selected for its innovation, performance, and measurable impact on customers and partners.
"This award reflects why 33% of the Top 250 MSSPs have already chosen Stellar Cyber," said Jeff Hill, Global Senior Director, Service Providers and MSSPs at Stellar Cyber. "Our platform allows MSPs to scale their security services at their own pace — crawl, walk, run — while our Infinity Partner Program delivers the business enablement, training, and go-to-market support that technology alone can't provide. Together, that empowers our partners to build world-class managed security practices and achieve real growth."
The Stellar Cyber Open Security Operations Platform is designed to address the challenges and competitive landscape faced by today's MSPs and MSSPs. It offers multi-tenancy management, the industry's most comprehensive list of multivendor cybersecurity tool integrations, powerful machine learning-based automation features, and AI-driven network detection and response (NDR) capabilities. MSPs and MSSPs can consolidate the number of security tools needed to manage their customers' environments, simplifying SOC operations and cutting operational costs. MSPs can optimize resources, grow margins, and gain a differentiated advantage, allowing them to deliver more comprehensive and unique service outcomes to clients. Most recently, Stellar Cyber launched the Infinity Partner Program for MSPs and MSSPs. This exciting new initiative delivers robust sales enablement resources to MSPs and MSSPs and drives strategic alignment with partners, empowering them to accelerate growth, expand service offerings, and further differentiate in an increasingly competitive market.
"It gives me great pleasure to recognize Stellar Cyber as a 2025 recipient of TMC's MSP Today Product of the Year Award for their innovative solution, the Stellar Cyber Open Security Operations Platform," said Rich Tehrani, CEO of TMC. "Our judges were thoroughly impressed not only by the strength and features of the product, but by Stellar Cyber's commitment to the Channel—empowering partners to deliver exceptional service and drive meaningful results for their clients."
Winners of the 2025 MSP Today Product of the Year Award will be featured on MSP Today, the definitive resource for managed service providers, as well as across TMCnet's media platforms.
About Stellar Cyber
By shining a bright light on the darkest corners of security operations, Stellar Cyber empowers organizations to see incoming attacks, know how to fight them, and act decisively – protecting what matters most. Stellar Cyber's award-winning open security operations platform includes AI-driven SIEM, NDR, Open XDR, and Multi-Layer AI™ under one license. With ⅓ of the top 250 MSSPs and over 14,000 customers worldwide, Stellar Cyber is one of the most trusted leaders in security operations. Learn more at https://stellarcyber.ai/.
About MSP Today
MSP Today is the premier online destination for MSPs (Managed Service Providers) and IT service providers worldwide. As the industry's leading web portal, we are committed to delivering timely and relevant news, cutting-edge product information, and invaluable insights to empower MSPs and IT professionals to thrive in today's rapidly evolving technology landscape. At MSP Today, we understand the challenges faced by MSPs and IT service providers in navigating the complexities of the modern business environment. Our dedicated team of expert journalists and industry analysts bring you the latest trends, best practices, and industry thought leadership to help you stay ahead of the curve. Whether you're seeking in-depth articles on emerging technologies, comprehensive product reviews, or actionable tips to optimize your IT services, MSP Today is your go-to resource for all things MSP-related. Join our vibrant community today and unlock the knowledge, resources, and networking opportunities to propel your MSP business to new heights. Follow MSP Today on Twitter or join our LinkedIn group. Subscribe or visit www.msptoday.com.
ABOUT TMC
For more than 20 years, TMC has been honoring technology companies with awards in various categories. These awards are regarded as some of the most prestigious and respected awards in the communications and technology sector worldwide. Winners represent prominent players in the market who consistently demonstrate the advancement of technologies. Each recipient is a verifiable leader in the marketplace.
TMC also provides global buyers with valuable insights to make informed tech decisions through our editorial platforms, live events, webinars, and online advertising. Leading vendors trust TMC, thought leadership, and our events for branding, thought leadership, and lead generation. Our live events, like the ITEXPO #TECHSUPERSHOW, deliver unmatched visibility, while our custom lead generation programs and webinars ensure a steady flow of sales opportunities. Display ads on trusted sites generate millions of impressions, boosting brand reputations. TMC offers a complete 360-degree marketing solution, from event management to content creation, driving SEO, branding, and marketing success. Learn more at www.tmcnet.com and follow @tmcnet on Facebook, LinkedIn, and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616313282/en/
Contacts
TMC Contact: Stephanie ThompsonManager, TMC Awards203-852-6800sthompson@tmcnet.com
Stellar Cyber Contact: Michelle BarryChameleon Collective for Stellar Cyber603-809-2748michelle.barry@chameleon.co
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
12 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
13 hours ago
- Business Wire
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit
